Stay updated on T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial page.

Latest updates to the T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial page
- Check3 days agoChange DetectedAdded a government funding lapse notice and updated the page revision to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check10 days agoChange DetectedThe page now includes a 'Show glossary' option and notes explaining the color-coded changes (green and red highlights). The revision metadata was updated to v3.4.0 and the No FEAR Act data item was removed.SummaryDifference0.6%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAdded Revision: v3.3.4 to the history and removed Revision: v3.3.3.SummaryDifference0.1%

- Check46 days agoChange DetectedAdded a new site revision entry, Revision: v3.3.3, to the history and removed HHS Vulnerability Disclosure and Revision: v3.3.2 from the footer.SummaryDifference0.1%

- Check74 days agoChange DetectedThe page header now displays Revision: v3.3.2, replacing Revision: v3.2.0.SummaryDifference0.1%

- Check81 days agoChange DetectedThe record history now shows new sections including Contacts/Locations, Eligibility, Arms and Interventions, Study Design, Study Description, and Study Status, expanding visibility of core trial details. A government funding notice was removed.SummaryDifference1.0%

Stay in the know with updates to T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial page.